Syros Pharmaceuticals (SYRS) News Today $7.79 +0.59 (+8.19%) (As of 12/29/2023 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Srinivas Akkaraju Purchases 904,977 Sharesamericanbankingnews.com - December 27 at 4:20 AMInsider Buying: Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Purchases 904,977 Shares of Stockmarketbeat.com - December 26 at 6:35 PMThese Biotech Stocks Climbed To New Peaks - Did You Invest?markets.businessinsider.com - December 26 at 9:56 AMSyros prices capital raise of $45.0 million via securities offeringseekingalpha.com - December 19 at 10:13 AMSyros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrantsfinance.yahoo.com - December 19 at 10:13 AMindividual investors who own 35% along with institutions invested in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) saw increase in their holdings value last weekfinance.yahoo.com - December 13 at 10:17 AMBuy Rating Justified by Syros Pharmaceuticals’ Strong Clinical Results and Market Potentialmarkets.businessinsider.com - December 7 at 2:44 PMWhy Is Blood Cancer Focused Syros Pharmaceuticals Stock Soaring Today?msn.com - December 6 at 6:16 PMSyros jumps after Phase 2 data for leukemia therapymsn.com - December 6 at 6:16 PMSyros Presents Positive Phase 2 Trial Data Of Tamibarotene Combination: Stock Up In Premarketmarkets.businessinsider.com - December 6 at 12:49 PMSyros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidinefinance.yahoo.com - December 6 at 7:33 AMPiper Sandler Keeps Their Buy Rating on Syros Pharmaceuticals (SYRS)markets.businessinsider.com - November 16 at 10:42 PMAnalysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS) and Kiora Pharmaceuticals (KPRX)markets.businessinsider.com - November 15 at 3:36 PMSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 15 at 3:36 PMSyros Pharmaceuticals Q3 Loss misses estimatesmarkets.businessinsider.com - November 14 at 8:25 AMSyros Reports Third Quarter 2023 Financial Results and Provides a Corporate Updatefinance.yahoo.com - November 14 at 8:25 AMPreview: Syros Pharmaceuticals's Earningsbenzinga.com - November 13 at 4:18 PMSyros Pharmaceuticals Inc SYRSmorningstar.com - November 12 at 8:29 PMSyros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023finance.yahoo.com - November 7 at 9:31 AMSyros CEO, chief scientist out as company cuts staff, programsbizjournals.com - October 4 at 9:28 AMSyros Pharmaceuticals Shares Fall 18% on Staff Cuts, CEO Retirementmarketwatch.com - October 3 at 7:29 AMSyros Pharmaceuticals to Cut 35% of Staff; CEO Simonian to Retiremarketwatch.com - October 2 at 9:24 AMSyros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Companyfinance.yahoo.com - October 2 at 9:24 AMPiper Sandler Reaffirms Their Buy Rating on Syros Pharmaceuticals (SYRS)markets.businessinsider.com - August 10 at 3:56 AMSyros Pharmaceuticals (SYRS) Gets a Buy from H.C. Wainwrightmarkets.businessinsider.com - August 9 at 7:53 AMQ2 2023 Syros Pharmaceuticals Inc Earnings Callfinance.yahoo.com - August 9 at 2:53 AMSyros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimatesfinance.yahoo.com - August 8 at 4:52 PMSyros Reports Second Quarter 2023 Financial Results and Provides a Corporate Updatefinance.yahoo.com - August 8 at 10:29 AMSyros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023finance.yahoo.com - August 1 at 3:44 PMPfizer To Terminate Development Pact With Syros Pharmaceuticals For Novel Therapies For Two Blood Disordersbenzinga.com - July 24 at 9:34 AMPfizer to end license deal with Syros for blood disorder therapiesfinance.yahoo.com - July 21 at 6:52 PMSyros Pharmaceuticals (SYRS) Price Target Increased by 22.53% to 164.73msn.com - July 6 at 8:32 PMSyros to Present at Sidoti June 2023 Virtual Small-Cap Conferencefinance.yahoo.com - June 8 at 10:33 AMSyros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meetingfinance.yahoo.com - May 25 at 7:49 PMOne Syros Pharmaceuticals Insider Raised Stake By 212% In Previous Yearfinance.yahoo.com - May 25 at 9:48 AMOne Syros Pharmaceuticals Insider Raised Stake By 212% In Previous Year \finance.yahoo.com - May 25 at 9:48 AMSyros Pharmaceuticals (NASDAQ: SYRS)fool.com - May 23 at 5:42 PMSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call Transcriptfinance.yahoo.com - May 13 at 10:31 AMJMP Securities Maintains Syros Pharmaceuticals (SYRS) Market Outperform Recommendationmsn.com - May 12 at 4:26 AMHC Wainwright & Co. Reiterates Syros Pharmaceuticals (SYRS) Buy Recommendationmsn.com - May 12 at 4:26 AMQ1 2023 Syros Pharmaceuticals Inc Earnings Callfinance.yahoo.com - May 10 at 10:22 PMSyros Reports First Quarter 2023 Financial Results and Provides a Corporate Updatefinance.yahoo.com - May 10 at 7:55 AMSyros to Present at JMP Securities 2023 Life Sciences Conferencefinance.yahoo.com - May 9 at 8:57 AMImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar?finance.yahoo.com - May 8 at 10:11 AMSyros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023finance.yahoo.com - May 3 at 10:48 AMSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - March 6 at 5:59 PMSyros Pharmaceuticals Stock (NASDAQ:SYRS), Guidance and Forecastbenzinga.com - March 5 at 6:43 PMSyros Pharmaceuticals, Inc. (SYRS) Q4 2022 Earnings Call Transcriptseekingalpha.com - March 4 at 7:41 PMSyros Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - March 4 at 2:40 PMQ4 2022 Syros Pharmaceuticals Inc Earnings Callfinance.yahoo.com - March 2 at 10:23 PM Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address SYRS Media Mentions By Week SYRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRS News Sentiment▼1.160.84▲Average Medical News Sentiment SYRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRS Articles This Week▼51▲SYRS Articles Average Week Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ETON News CARM News ABEO News ANIX News BLRX News PMVP News KNTE News CTXR News GBIO News XBIT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:SYRS) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.